Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Dr. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. The company stated that Dr. Fang has played a key role in advancing its clinical development efforts and will lead scientific strategy through upcoming clinical and regulatory milestones. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The company’s lead drug candidate, buntanetap (formerly posiphen), has shown promise in earlier trials. The appointment of Dr. Fang as CSO signals the company’s commitment to advancing its pipeline toward regulatory approval. For more information, visit www.annovisbio.com.
The full press release is available at https://ibn.fm/c9jdt. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
